GLP-1 Coverage by State

How many states cover GLP-1s under Medicaid for weight loss?

Checking each state's own documents between September 20, 2026 and October 13, 2026, 10 of 50 state Medicaid programs cover at least one weight-loss GLP-1 (Wegovy, Zepbound, Saxenda, Foundayo or oral Wegovy) for adult members: Delaware, Kansas, Michigan, Minnesota, Mississippi, Missouri, North Carolina, Tennessee, Virginia, and Wisconsin. Several cover only some drugs or only severe obesity - Michigan requires morbid obesity (BMI 40 or higher), Virginia requires a BMI over 40 (or over 37 with a qualifying condition), and Missouri and Wisconsin cover Zepbound and Foundayo but not Wegovy. Most other state Medicaid programs cover GLP-1s only for type 2 diabetes, and some also for cardiovascular risk, MASH or sleep apnea. Coverage is volatile: 7 programs have ended it in 2026 - California, New Hampshire, Pennsylvania, and South Carolina (January 1), Utah (June 30), Massachusetts (July 3), and Rhode Island (October 1).

Source: KFF, Medicaid Coverage of and Spending on GLP-1s (13 states in its January 2026 map)

Why do so few states cover it?

Cost is the main reason states have given. California ended Medi-Cal's coverage effective January 1, 2026 under its 2025-26 budget, and Rhode Island ended its coverage on October 1, 2026 under its FY2027 budget. Delaware's state employee plan is a documented example of spending running far over the estimate: its consultant told the State Employee Benefits Committee on March 9, 2026 that weight-loss drug spending was $14.2 million in fiscal 2024 against a $1.8 million estimate from the plan's pharmacy benefit manager, and $53.3 million in fiscal 2025. States weighing coverage generally compare near-term drug spend against projected long-term savings from fewer cardiovascular events, less type 2 diabetes progression and less bariatric surgery, and many have decided the near-term cost is too high.

Source: Delaware State Employee Benefits Committee, March 9, 2026 presentation (slide 16)

What does "state employee plan covers" mean if I'm not a state employee?

Nothing directly. A state's own employee health plan is a large, well-documented purchaser, so its rules show how one big employer is handling the cost, but they do not decide what your own plan or your state's Medicaid program covers. Checking each plan's own documents between September 20, 2026 and October 13, 2026, 5 state employee plans cover weight-loss GLP-1s as an ordinary benefit and 13 cover them with limits (a required program, a BMI cutoff, a pilot or a large added copay); 23 exclude them, and 9 could not be verified because no current plan document that settles it could be read. Plan terms reset each plan year, so a plan's 2027 rules may differ from what is shown.

Does Medicaid expansion status affect GLP-1 coverage?

Not directly, but the two questions get conflated. "Medicaid expansion" refers to a state's decision to extend Medicaid eligibility to more low-income adults under the ACA - it is a separate policy question from whether that state's Medicaid formulary covers GLP-1s for weight loss once someone is enrolled. A state can have expanded Medicaid broadly and still exclude weight-loss GLP-1s from its drug formulary, and vice versa.

What if my state does not cover GLP-1s under Medicaid?

Check whether you qualify under a diabetes indication instead (Ozempic or Mounjaro, not Wegovy or Zepbound), since nearly every state Medicaid program covers GLP-1s for type 2 diabetes even where weight-loss coverage is excluded. If that path is closed, direct manufacturer self-pay (NovoCare for Wegovy, LillyDirect for Zepbound) remains available at cash prices regardless of your insurance status - Medicaid enrollees cannot use the manufacturer copay savings cards (federally excluded), but can use the direct self-pay cash price like anyone else.